Background: When managing patients who require repeated venous access, gaining a viable intravenous route has been problematic. To improve the situation, various studies on techniques for venous access have been conducted. The aim of this study is to evaluate the clinical results of complications following totally implanted central venous access port (TICVAP) insertion. Methods: A retrospective analysis was conducted on 163 patients, from December 2008 to March 2013. The occurrence of complications was studied in three separate periods of catheter use: the intraoperative period, postoperative period, and period during the treatment. Results: A total of 165 cases of TICVAP insertions involving 156 patients were included in the final analysis. There were 35 complications (21%) overall. Among these, 31 cases of complications (19%) occurred during the treatment period and the other 4 cases were intraoperative and postoperative complications (2%). There were no statistically significant differences in age and gender of the patients between the two groups to be risk factors (p=0.147, p=0.08). Past history of chemotherapy, initial laboratory findings, and the locations of TICVAP insertion also showed no statistical significance as risk factors (p＞0.05). Conclusion: Because the majority of complications occurred after port placement and during treatment, meticulous care and management and appropriate education are necessary when using TICVAPs.
INTRODUCTION
When managing patients who require repeated venous access, particularly cancer patients, establishing a patent intravenous line has always been problematic, because repeated venous punctures may lead to the rupturing of veins, thrombophlebitis, and physical and psychological stress to patients [1] . To address these problems, various studies have been conducted on the access techniques of the totally implanted central venous access port (TICVAP) and the Hickman catheter, that is, the tunneled, cuffed silastic catheters that were first described by Broviac et al. [2] and subsequently modified by Hickman and associates.
However, although TICVAPs are currently accepted as relatively safe and appropriate for use in cancer patients, we have experienced several cases of complications, in both the
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METHODS

1) Study population and measurements
This study was approved by the institutional review board at Konyang University Hospital. A retrospective analysis was One hundred and sixty-three patients underwent the insertion of TICVAPs, and 6 of them were excluded due to a lack of laboratory data. One additional patient was excluded from analysis because the patient's TICVAP implantation had failed due to venous anomalies. Thus, 156 patients were included in the final analysis.
The patient's age, gender, site of primary tumor, catheter type, history of previous chemotherapy, and laboratory results were recorded and classified as patient-related risk factors.
The laboratory results, including white blood cell (WBC) counts, platelets, hemoglobin, partial thromboplastin time (PTT), and activated PTT were obtained within 14 days of the operation date. In addition, the date of catheter removal, as well as complications related to the catheters, reimplantation, reimplanted catheter removal, and death, were recorded.
The occurrence of complications was studied in three separate periods: intraoperative period, postoperative period, and period during the treatment involving the use of the catheter.
Postoperative complications following the catheter implantation were apparent even before the treatment began. A total of 165 TICVAPs were placed in 156 patients. Nine patients each received 2 ports. All of their TICVAPs had been removed after their first chemotherapy administration but reinserted due to the recurrence or metastasis of cancer during this period. The follow-up period for this study for each patient lasted from the date of TICVAP insertion to the date of device removal, death, or last recorded date.
2) Surgical procedures
The TICVAP implantation procedures were conducted under sterile conditions in the operating room by experienced general thoracic and cardiovascular surgeons and residents in training, with a portable fluoroscopic device (X-ray image intensifier, C-arm). For internal jugular vein approaches, portable ultrasonography was used. 
3) Catheter care
TICVAPs were cared for by experienced nurses, including cleaning the insertion site with chloorhexidine and covering (60) 59 (38) 38 (24) 14 (9) 12 (8) 12 (8) 5 (3) 5 (3) 11 (7) 165
Values are presented as mean±standard deviation or number (%). Values are presented as number (%).
the insertion site dressing twice a week or more often if indicated. The TIAP was flushed with 9 mL of 0.9% saline solution and 1 mL of heparin after administration of medication or blood products. If the TIAP was not used for a long time, the port was flushed every 5 to 6 weeks.
4) Statistical analysis
The data were analyzed using the PASW SPSS ver. 18.0 (SPSS Inc., Chicago, IL, USA). Continuous variables were compared using the 2-tailed Student t-test or Mann-Whitney U-test and described as mean±standard deviation or median (range). Categorical variables were compared using a chi-square test or Fisher's exact test, as applicable. A p-value of less than 0.05 was considered to be statistically significant.
RESULTS
Demographic data are shown in Table 1 . Of 156 patients, 93 were females and 63 were males; among them, 9 patients In 2 of these 3 cases, the TICVAPs were removed because of the dehiscence of the operation site, while in the third case, spontaneous resolution occurred. In the 3 thrombus cases (2%), the complications were treated with 10% heparinized saline injection through the TICVAPs.
Risk factors that could affect the occurrence of complications were collected and analyzed (Table 3 ). There were no statistically significant differences between the two groups in terms of the age and the gender of the patients (p=0.147 and p=0.08). Nor were there any statistically significant differences in past history of chemotherapy, initial laboratory findings, or the locations of TICVAP access (p＞0.05).
DISCUSSION
The TICVAP, also called a port or a chemoport, is a small reservoir connected to a venous catheter and is positioned in the subcutaneous tissue. The use of TICVAPs started in the early 1980s in oncologic patients [3] and remains an integral part of their daily clinical routine [4] .
As compared to external venous access, TICVAPs have many advantages for the patient who requires a continuous intravenous line, such as greater cost-effectiveness, a lower risk of infection, and thrombosis [5] [6] [7] . However, TICVAPs may be associated with several complications, most of which can be effectively prevented [8] .
In a retrospective study of the risk factors of TICVAP involving 561 implantation cases by Ignatov et al. [9] , complications occurred in 104 cases (19%), and most of these were late complications (96 cases, 17%). They reported that a body mass index (BMI) of more than 28.75 had a significant influence on the rate of complications and stated that the age, the type of cancer, and the presence of metastasis were not patient-related risk factors for complications. However, another study has shown BMI not to be a patient-related risk factor.
In a prospective study of 815 cases by Narducci et al. [10] , the overall morbidity rate was 16.1%, with infection as the main cause of complications. In this study, baseline BMI, type of cancer, and history of chemotherapy showed little correlation with complications. Further, they concluded that early first use of an implanted device within 7 days from placement and a jugular vein approach were factors significantly related to complications (p=0.003 and p=0.005, respectively).
In addition to the factors mentioned above, the location of the catheter tip and the choice of vein for intravenous access were highly significant independent prognostic factors.
Complication rates and the rates of port removal because of (9) 6 (4) 3 (2) 3 (2) 4 (3) Values are presented as number (%). TICVAP, totally implanted central venous access.
malfunction were significantly higher when the port was located in the peripheral part of the upper venous system or inserted through the subclavian vein [9] . Araujo et al. [11] showed access via the internal jugular vein rather than the subclavian vein to be associated with lower rates of immediate complications, catheter malpositioning, long-term morbidity (including venous thrombosis), and catheter malfunction.
However, Narducci et al. [10] As for WBC counts as a patient-related factor, Gutierrez and Gollin [13] noted that the exclusion of neutropenic children (＜0.5×10 9 /L) from TICVAPs significantly lowers the rate of complications. In our study, however, there were no neutropenic patients and the WBC count was not a risk factor (p=0.582).
The position of the catheter tip of the TICVAP is also important for long-term maintenance. Many studies have reported that catheter tips should be placed at the SVC-right atrial junction [14, 15] . The United States Food and Drug Administration guidelines suggest that the catheter tip should not be positioned in the right atrium [16] . When the catheter is positioned in the right atrium, it may cause cardiac-related complications. To determine the appropriate length of the catheter, we used portable fluoroscopy in every case of TICVAP insertion. The optimal catheter length was determined under fluoroscopic guidance by measuring the distance from the pocket for the TICVAP to the angle of the right main bronchus and trachea. Variable studies about the SVC-right atrium junction level on the chest radiograph [17, 18] have been reported, but in our study, there were no late complications related to the catheter length.
In our study, patient characteristics such as the age, gender, site of primary tumor, catheter type, history of previous chemotherapy, and laboratory results did not influence the overall incidence of complications. In common with other studies [9, 10] , the main complication observed in our study was infection (Table 4) , occurring in 15 cases of implantation (9%).
In conclusion, a majority of complications of TICVAPs occurred after port placement and during treatment. To prevent complications of TICVAPs, it is essential to provide meticulous care and management and give appropriate education about TICVAPs, particularly during treatment.
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